Avalo Therapeutics, Inc. 8-K

What Happened
On May 13, 2026, Avalo Therapeutics, Inc. (AVTX) announced its financial results for the quarter ended March 31, 2026 via a press release and furnished that release as Exhibit 99.1 to a Form 8-K (Item 2.02). The Form 8-K discloses the company’s reported results of operations and financial condition for the stated quarter.

Key Details

• Form 8-K filed on May 13, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• The press release covers quarterly financial results for the period ended March 31, 2026 and is furnished as Exhibit 99.1.
• The filing also includes the Inline XBRL cover page as Exhibit 104.

Why It Matters
Quarterly results provide updated information on Avalo’s earnings, revenue, cash position and operational progress — key inputs for investors assessing the company’s financial health and near-term outlook. Retail investors should read the furnished press release and related SEC filings for the detailed numbers (revenue, net income/loss, cash runway) and any management commentary that could influence the stock or investment decisions.